Weekly aspergillosis update – 20 April 2026

This week’s papers point in three useful directions for aspergillosis research: better diagnosis, more precise immune modulation, and improved antifungal pharmacology modelling. The most directly relevant study for day-to-day human aspergillosis care is a new paper on blood metagenomic next-generation sequencing (mNGS) for invasive pulmonary aspergillosis.

1. Blood metagenomic next-generation sequencing for invasive pulmonary aspergillosis

Chen Y, Tang X, Lu S, Guo L, Wang L, Min L, Niu T, Zhou Y.
The diagnostic and prognostic utility of blood metagenomic next-generation sequencing for invasive pulmonary aspergillosis.
Microbiology Spectrum, 17 April 2026.
View on PubMed (PMID: 41995327)

This study addresses one of the hardest clinical problems: distinguishing true invasive pulmonary aspergillosis from colonisation when Aspergillus is detected. A reliable blood-based test could be especially useful where bronchoscopy is not possible or results are unclear.

At present, this should be seen as promising rather than practice-changing, but it is exactly the type of work needed to improve early and accurate diagnosis.

2. Gene delivery of immunomodulatory cytokines to the lung

Makuyana N et al.
Gene delivery of immunomodulatory cytokines to the lung preserves respiratory function during inflammatory challenge.
Science Immunology, 17 April 2026.
View on PubMed (PMID: 41996474)

This preclinical study explores whether delivering immunomodulatory cytokines directly to the lungs can reduce damaging inflammation. The work is linked to influenza-associated pulmonary aspergillosis, where immune-driven lung injury can be severe.

The key idea is that fungal lung disease is not only about infection, but also about how the immune system responds. This represents a shift toward combining antifungal treatment with targeted immune modulation—although this approach is still at an early, experimental stage.

3. Isavuconazole pharmacokinetic modelling (preprint)

Choules MP et al.
Development of an Isavuconazole Physiologically-based Pharmacokinetic Model for Adult and Pediatric Populations.
Research Square, 17 April 2026 (preprint).

This study uses physiologically based pharmacokinetic (PBPK) modelling to predict how isavuconazole behaves in adults and children, including potential drug–drug interactions.

The findings suggest broadly similar interaction risks across age groups, but highlight greater uncertainty and caution in children under 3 years, particularly with drugs such as digoxin and warfarin.

As a preprint, this is best viewed as supportive pharmacology data, not a change to clinical practice.

4. Histopathology in infectious disease diagnosis

Boubacar E et al.
Histopathological Diagnosis of Infectious Diseases: Experience From a Tertiary Care Center in a Sub-Saharan African Country.
International Journal of Surgical Pathology, 16 April 2026.
View on PubMed (PMID: 41989331)

This broader study included a small number of aspergillosis cases and highlights the continued importance of histopathology, particularly when infections mimic cancer or other conditions.

5. Avian aspergillosis biomarker research

Vieu S et al.
Falcon plasma proteomics to improve avian aspergillosis diagnosis.
Journal of Proteomics, 14 April 2026.
View on PubMed (PMID: 41990917)

This veterinary study explores new plasma biomarkers for diagnosing aspergillosis in birds. While not directly applicable to human care, it reflects a broader research trend toward earlier, less invasive diagnosis.

What matters most this week?

The most important development is the blood mNGS study, which targets a real diagnostic gap. The immunology paper is conceptually important for future treatments, while the isavuconazole modelling work supports ongoing improvements in antifungal use.

Bottom line

This week reinforces three key directions in aspergillosis research:

• Earlier and more accurate diagnosis
• Better understanding of immune-driven lung damage
• More precise antifungal drug use and interaction modelling